Abstract
Ex vivo expansion of hematopoietic stem cells has been explored in the fields of stem cell biology, gene therapy and clinical transplantation. Recently, we demonstrated the existence of a circulating myogenic progenitor expressing the CD133 antigen. The relative inability of circulating CD133+ stem cells to reproduce themselves ex vivo imposes substantial limitations on their use for clinical applications in muscular dystrophies. Here we report that the use of cluster-assembled nanostructured titanium dioxide (ns-TiO2) substrates, in combination with cytokine enriched medium, enables high-level expansion of circulating CD133+ stem cells in vitro. Furthermore, we demonstrate that expanded circulating CD133+ stem cells retain their in vitro capacity to differentiate into myogenic cells. The exploitation of cluster-assembled ns-TiO2 substrates for the expansion of CD133+ stem cells in vitro could therefore make the clinical application of these stem cells for the treatment of muscle diseases practical.
| Original language | English |
|---|---|
| Pages (from-to) | 5385-5396 |
| Number of pages | 12 |
| Journal | Biomaterials |
| Volume | 31 |
| Issue number | 20 |
| DOIs | |
| Publication status | Published - Jul 2010 |
Fingerprint
Keywords
- Cell culture
- Muscular dystrophy
- Nanotopography
- Stem cell
- Surface treatment
- Titanium oxide
ASJC Scopus subject areas
- Biomaterials
- Bioengineering
- Ceramics and Composites
- Mechanics of Materials
- Biophysics
Cite this
Ex vivo expansion of human circulating myogenic progenitors on cluster-assembled nanostructured TiO2 . / Belicchi, Marzia; Erratico, Silvia; Razini, Paola; Meregalli, Mirella; Cattaneo, Alessandra; Jacchetti, Emanuela; Farini, Andrea; Villa, Chiara; Bresolin, Nereo; Porretti, Laura; Lenardi, Cristina; Milani, Paolo; Torrente, Yvan.
In: Biomaterials, Vol. 31, No. 20, 07.2010, p. 5385-5396.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ex vivo expansion of human circulating myogenic progenitors on cluster-assembled nanostructured TiO2
AU - Belicchi, Marzia
AU - Erratico, Silvia
AU - Razini, Paola
AU - Meregalli, Mirella
AU - Cattaneo, Alessandra
AU - Jacchetti, Emanuela
AU - Farini, Andrea
AU - Villa, Chiara
AU - Bresolin, Nereo
AU - Porretti, Laura
AU - Lenardi, Cristina
AU - Milani, Paolo
AU - Torrente, Yvan
PY - 2010/7
Y1 - 2010/7
N2 - Ex vivo expansion of hematopoietic stem cells has been explored in the fields of stem cell biology, gene therapy and clinical transplantation. Recently, we demonstrated the existence of a circulating myogenic progenitor expressing the CD133 antigen. The relative inability of circulating CD133+ stem cells to reproduce themselves ex vivo imposes substantial limitations on their use for clinical applications in muscular dystrophies. Here we report that the use of cluster-assembled nanostructured titanium dioxide (ns-TiO2) substrates, in combination with cytokine enriched medium, enables high-level expansion of circulating CD133+ stem cells in vitro. Furthermore, we demonstrate that expanded circulating CD133+ stem cells retain their in vitro capacity to differentiate into myogenic cells. The exploitation of cluster-assembled ns-TiO2 substrates for the expansion of CD133+ stem cells in vitro could therefore make the clinical application of these stem cells for the treatment of muscle diseases practical.
AB - Ex vivo expansion of hematopoietic stem cells has been explored in the fields of stem cell biology, gene therapy and clinical transplantation. Recently, we demonstrated the existence of a circulating myogenic progenitor expressing the CD133 antigen. The relative inability of circulating CD133+ stem cells to reproduce themselves ex vivo imposes substantial limitations on their use for clinical applications in muscular dystrophies. Here we report that the use of cluster-assembled nanostructured titanium dioxide (ns-TiO2) substrates, in combination with cytokine enriched medium, enables high-level expansion of circulating CD133+ stem cells in vitro. Furthermore, we demonstrate that expanded circulating CD133+ stem cells retain their in vitro capacity to differentiate into myogenic cells. The exploitation of cluster-assembled ns-TiO2 substrates for the expansion of CD133+ stem cells in vitro could therefore make the clinical application of these stem cells for the treatment of muscle diseases practical.
KW - Cell culture
KW - Muscular dystrophy
KW - Nanotopography
KW - Stem cell
KW - Surface treatment
KW - Titanium oxide
UR - http://www.scopus.com/inward/record.url?scp=77952583673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952583673&partnerID=8YFLogxK
U2 - 10.1016/j.biomaterials.2010.03.021
DO - 10.1016/j.biomaterials.2010.03.021
M3 - Article
VL - 31
SP - 5385
EP - 5396
JO - Biomaterials
JF - Biomaterials
SN - 0142-9612
IS - 20
ER -